• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Procept BioRobotics touts slew of Aquablation therapy study results

Procept BioRobotics touts slew of Aquablation therapy study results

May 20, 2019 By Fink Densford

Procept BioRobotics

Procept BioRobotics today released results from a slew of studies of its Aquablation therapy provided with its Aquabeam robotic system, touting the device as durable, safe and effective.

The AquaBeam system uses a robotically controlled waterjet to ablate prostate tissue without needing heat, the Redwood Shores, Calif.-based company said

Results from the trials were presented at the American Urological Association’s annual meeting, Procept BioRobotics said.

Procept BioRobotics presented one-year data from the WATER II study exploring the use of Aquablation therapy in 101 men with prostates 80 to 150 mL in size. Results from the study showed that Aquablation was a safe surgical alternative for patients with large prostate glands, with durable outcomes reported at one year alongside fast operating times, short hospitalizations and maintenance of antegrade ejaculatory function.

The company also presented two-year follow-up data from the WATER study comparing the safety and efficacy of Aquablation therapy to transurethral resection of the prostate. Results showed longer term, durable evidence of the safety and effectiveness of the device in treating patients with lower urinary tract symptoms due to BPH with prostates between 30 and 80 mL in size, Procept BioRobotics said.

In its last presentation, the company touted single-center results from a consecutive, 180-patient cohort treated with Aquablation therapy between September 2017 and June 2018, with results showing safety and efficacy measures consistent with the WATER and WATER II outcomes in a real-life setting.

“These longer-term study results, and the recent addition of Aquablation therapy to the AUA surgical practice guidelines for BPH, position Aquablation therapy as a new standard of care for patients suffering from BPH. Aquablation therapy is the only BPH treatment that democratizes BPH surgery by delivering predictable and reproducible outcomes from day one, independent of prostate anatomy, size or complexity – and it does so regardless of surgeon experience,” prez & CEO Nikolai Aljuri said in a press release.

In March, Hydrocision said that it inked an exclusive worldwide licensing deal to allow Procept Biorobitics to use its pump cartridge technology for urological applications.

Filed Under: Clinical Trials, Surgical Robotics, Urology Tagged With: Procept BioRobotics

More recent news

  • Virtuoso Surgical reports first cases with robotic endoscopy system, plans FDA IDE submission
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Philips prices $1.1B offering to pay off debt, finance green projects
  • Pixee Medical reports first knee arthroplasty cases using its augmented reality nav tech
  • Alpheus Medical raises $52M for ultrasound-activated tumor therapy

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy